New directions in natural killer cell-based immunotherapy of human cancer

Bibliography

• ROSENBERG SA: Progress in human tumor immunology and immunotherapy. Nature (2001) 411:380–384.
   PubMed Web of Science ®Google Scholar
• HOROWITZ MM, GALE RP, SONDEL PM et al.: Graft-versus-leukemia reactions after bone marrow transplantation. Blood(1990) 75:555–562.
   PubMed Web of Science ®Google Scholar
• COLLINS RH JR SHPILBERG 0, DROBYSKI WR et al.: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. I Clin. Oncol (1997) 15:433–444.
   Google Scholar
• KHOURI IF, SALIBA RM, GIRALT SAet al.: Nonablative allogeneic hematopoietictransplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood (2001) 98:3595–3599.
   Google Scholar
• CHILDS R, SRINIVASAN R: Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. Cancer (2002) 8:2–11.
   Web of Science ®Google Scholar
• SLAVIN S, NAGLER A, SHAPIRA MY, AKER M, GABRIEL C, OR R: Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation.Clin. brununol. (2002) 22:64–69.
   Google Scholar
• YEE C, RIDDELL SR, GREENBERG PD: Prospects for adoptive T cell therapy. Can: Opin. Innnunol. (1997) 9:702–708.
   PubMed Web of Science ®Google Scholar
• ROBERTSON MJ, RITZ J: Biology and clinical relevance of human natural killer cells. Blood(1990) 76:2421–2438.
   PubMed Web of Science ®Google Scholar
• TRINCHIERI G: Biology of natural killer cells. Adv. brununol. (1989) 47:187–376.
   PubMed Web of Science ®Google Scholar
• THOMPSON JA, SHULMAN KL, BENYUNES MC et al.: Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.Clin. Oncol (1992) 10:960–968.
   Google Scholar
• CALIGIURI MA, MURRAY C, ROBERTSON MJ et al.: Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.1 Clin. Invest. (1993) 91:123–132.
   Google Scholar
• SOIFFER RJ, MURRAY C, GONIN R, RITZ J: Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood (1994) 84:964–971.
   PubMed Web of Science ®Google Scholar
• COOPER MA, FEHNIGER TA, CALIGIURI MA: Biology of human natural killer cell subsets. Trends Immunol (2001) 22:633–640.
   PubMed Web of Science ®Google Scholar
• ••Detailed review of the biology of NK cellsubsets.
   Google Scholar
• COOPER MA, FEHNIGER TA, TURNER SC et al.: Human natural killer cells: a unique innate immunoregulatory role for the CD56 (bright) subset. Blood (2001) 97:3146–3151.
   PubMed Web of Science ®Google Scholar
• ••An important paper presenting evidencefor an irnmunoregulatory role of the CD56bright NK cell subset, and the hypothesis that the CD56bright and CD56dim NK cell subsets are functionally different rather than different stages in NK cell development.
   Google Scholar
• CALIGIURI MA, ZMUIDZINAS A, MANLEY TJ, LEVINE H, SMITH KA, RITZ J: Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. " Exp. Med. (1990) 171:1509–1526.
   Google Scholar
• BAUME DM, ROBERTSON MJ, LEVINE H, MANLEY TJ, SCHOW PW, RITZ J: Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. Ear: Immunol (1992) 22:1–6.
   PubMed Web of Science ®Google Scholar
• NAGLER A, LANIER LL, CWIRLA S, PHILLIPS JH: Comparative studies of human FcRIII-positive and negative natural killer cells. J. Immunol (1989) 143:3183–3191.
   PubMed Web of Science ®Google Scholar
• ELLIS TM, FISHER RI: Functional heterogeneity of Leu 19'brighf+ and Leu 19'dim'+ lymphokine-activated killer cells. Immunol (1989) 142:2949–2954.
   Web of Science ®Google Scholar
• ROBERTSON MJ, SOIFFER RJ, WOLF SF et al.: Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. I Exp. Med. (1992) 175:779–788.
   PubMed Web of Science ®Google Scholar
• VOSS SD, DALEY J, RITZ J, ROBERTSON MJ: Participation of the CD94 receptor complex in costimulation of human natural killer cells.' Immunol (1998) 160: 1618-1626.
   Google Scholar
• ANDRE P, SPERTINI 0, GUIA S et al: Modification of P-selectin glycoprotein ligand-1 with a natural killer cell-restricted sulfated lactosamine creates an alternateligand for L-selectin. Proc. Natl. Acad. Sci. USA (2000) 97:3400–3405.
   PubMed Web of Science ®Google Scholar
• LJUNGGREN HG, KARRE K: In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today (1990) 11:237–244.
   PubMedGoogle Scholar
• ZULSTRA M, AUCHINCLOSS H JR, LORING JM, CHASE CM, RUSSELL PS, JAENISCH R Skin graft rejection by beta 2-microglobulin-deficient mice. J. Exp. Med. (1992) 175:885–893.
   PubMed Web of Science ®Google Scholar
• ROUTES JM: IFN increases class I MHC antigen expression on adenovirus-infected human cells without inducing resistance to natural killer cell killing.' Immunol (1992) 149:2372–2377.
   Web of Science ®Google Scholar
• MALNATI MS, LUSSO P, CICCONE E, MORETTA A, MORETTA L, LONG EO: Recognition of virus-infected cells by natural killer cell clones is controlled by polymorphic target cell elements. J. Exp. Med. (1993) 178:961–969.
   PubMed Web of Science ®Google Scholar
• LANIER LL: Activating and inhibitory NKcell receptors. Adv. Exp. Med. Biol. (1998) 452:13–18.
   PubMed Web of Science ®Google Scholar
• •Detailed review of NK cell receptor biology.
   Google Scholar
• LOPEZ-BOTET M, BELLON T: Natural killer cell activation and inhibition by receptors for MHC class I. Curt: Opin. Immunol (1999) 11:301–307.
   PubMed Web of Science ®Google Scholar
• •Review of KIRs.
   Google Scholar
• MORETTA A, BOTTINO C, VITALE M et al.: Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Ann. Rev Immunol (2001) 19:197–223.
   PubMed Web of Science ®Google Scholar
• •Review of activating NK cell receptor biology.
   Google Scholar
• FARAG SS, FEHNIGER TA, RUGGERI L, VELARDI A, CALIGIURI MA: Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood (2002) 100:1935–1947.
   PubMed Web of Science ®Google Scholar
• BAKKER AB, WU J, PHILLIPS JH, LANIER LL: NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. Hum. Immunol (2000) 61:18–27.
   PubMed Web of Science ®Google Scholar
• •Review of intracellular pathways of signal transduction by of NK cell receptors.
   Google Scholar
• LANIER LL: Follow the leader: NK cell receptors for classical and nonclassical MHC class I. Cell (1998) 92:705–707.
   PubMed Web of Science ®Google Scholar
• LOPEZ-BOTET M, BELLON T, LLANO M, NAVARRO F, GARCIA P,DE MIGUEL M: Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum. Immunol (2000) 61:7–17.
   PubMed Web of Science ®Google Scholar
• VALES-GOMEZ M, REYBURN HT, MANDELBOIM M, STROMINGERJL: Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors. Immunity (1998) 9:337–344.
   PubMed Web of Science ®Google Scholar
• MORETTA A, BOTTINO C, VITALE M et al.: Receptors for HLA class-I molecules in human natural killer cells. Ann. Rev Immunol (1996) 14:619–648.
   PubMed Web of Science ®Google Scholar
• WAGTMANN N, RAJAGOPALAN S, WINTER CC, PERUZZI M, LONG EO: Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and functional transfer. Immunity (1995) 3:801–809.
   PubMed Web of Science ®Google Scholar
• LANIER LL: NK cell receptors. Ann. Rev Immunol (1998) 16:359–393.
   PubMed Web of Science ®Google Scholar
• RAJAGOPALAN S, LONG EO: A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. " Exp. Med. (1999) 189:1093–1100.
   PubMed Web of Science ®Google Scholar
• IBRAHIM EC, GUERRA N, LACOMBE MJ et al.: Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res. (2001) 61:6838–6845.
   PubMed Web of Science ®Google Scholar
• WIENDL H, MITSDOERFFER M, HOFMEISTER V et al: A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape.Immunol (2002) 168:4772–4780.
   Web of Science ®Google Scholar
• UGUREL S, REINHOLD U, TILGEN W HLA-G in melanoma: a new strategy to escape from immunosurveillance? Onkologie (2002) 25:129–134.
   PubMed Web of Science ®Google Scholar
• UROSEVIC M, WILLERS J, MUELLER B, KEMPF W, BURG G, DUMMER R: HLA-G protein up-regulation in primary cutaneouslymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood (2002) 99:609–617.
   PubMed Web of Science ®Google Scholar
• BAUER S, GROH V, WU J et al.: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (1999) 285:727–729.
   PubMed Web of Science ®Google Scholar
• •Discusses the biology of MICA/B as ligands for NKG2D.
   Google Scholar
• SIVORI S, PAROLINI S, MARCENARO E et al.: Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of247neuroblastoma and glioblastoma cell lines..1 Neuroimmunol (2000) 107:220–225.
   Google Scholar
• PENDE D, CANTONI C, RIVERA P et al.: Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Ear: j Immunol. (2001) 31:1076–1086.
   PubMed Web of Science ®Google Scholar
• ••Relative roles of NKG2D and NCR in therecognition and killing of tumour cells by NK cells.
   Google Scholar
• COSTELLO RT, SIVORI S, MARCENARO E et al.: Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood (2002) 99:3661–3667.
   PubMed Web of Science ®Google Scholar
• ••Presents evidence for a reduction inexpression and function of activating NK cell receptors in patients with advanced leukaemia.
   Google Scholar
• BAHRAM S: MIC genes: from genetics to biology. Adv. Immunol. (2000) 76:1–60.
   PubMed Web of Science ®Google Scholar
• WU J, SONG Y, BAKKER AB et al.: An activating immunoreceptor complex formed by NKG2D and DAP10. Science (1999) 285:730–732.
   PubMed Web of Science ®Google Scholar
• SUTHERLAND CL, CHALUPNY NJ, COSMAN D: The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions. Immunol Rev (2001) 181:185–192.
   PubMed Web of Science ®Google Scholar
• •A significant paper characterising the ULBPs as important ligands for NKG2D.
   Google Scholar
• COSMAN D, MULLBERG J, SUTHERLAND CL et al.: ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity (2001) 14:123–133.
   PubMed Web of Science ®Google Scholar
• GROH V, RHINEHART R, SECRIST H, BAUER S, GRABSTEIN KH, SPIES T: Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Nati Acad. Sci. USA (1999) 96:6879–6884.
   PubMed Web of Science ®Google Scholar
• GROH V, BAHRAM S, BAUER S, HERMAN A, BEAUCHAMP M, SPIES T: Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Nati Acad. Sci. USA (1996) 93:12445–12450.
   PubMed Web of Science ®Google Scholar
• GROH V, RHINEHART R, RANDOLPH-HABECKER J, TOPP MS,RIDDELL SR, SPIES T: Costimulation ofCD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol (2001) 2:255–260.
   PubMed Web of Science ®Google Scholar
• CERWENKA A, BARON JL, LANIER LL: Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA (2001) 98:11521–11526.
   PubMed Web of Science ®Google Scholar
• PESSINO A, SIVORI S, BOTTINO C et al.: Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J. Exp. Med. (1998) 188:953–960.
   PubMed Web of Science ®Google Scholar
• SUTHERLAND CL, CHALUPNY NJ, SCHOOLEY K, VANDENBOS T, KUBIN M, COSMAN D: UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. " Immunol (2002) 168:671–679.
   PubMed Web of Science ®Google Scholar
• SILICIANO RF, PRATT JC, SCHMIDT RE, RITZ J, REINHERZ EL: Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature (1985) 317:428–430.
   PubMed Web of Science ®Google Scholar
• LANIER LL, RUITENBERG JJ, PHILLIPS JH: Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes." Immunol (1988) 141:3478–3485.
   PubMed Web of Science ®Google Scholar
• TIMONEN T, PATARROYO M, GAHMBERG CG: CD1 la-c/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing. J. Immunol. (1988) 141:1041–1046.
   PubMed Web of Science ®Google Scholar
• CARBONE E, RUGGIERO G, TERRAZZANO G et al: A new mechanism of NK cell cytotoxicity activation: the CD4O-CD40 ligand interaction. Journal of Experimental Medicine (1997) 185:2053–2060.
   PubMed Web of Science ®Google Scholar
• BORREGO F, ROBERTSON MJ, RITZ J,PENA J, SOLANA R: CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology (1999) 97:159–165.
   PubMed Web of Science ®Google Scholar
• TANGYE SG, CHERWINSKI H, LANIER LL, PHILLIPS JH: 2B4-mediated activation of human natural killer cells. Immunol (2000) 37:493–501.
   Web of Science ®Google Scholar
• SIVORI S, PAROLINI S, FALCO M et al.:2B4 functions as a co-receptor in human NK cell activation. Ear. J Immunol (2000) 30:787–793.
   PubMed Web of Science ®Google Scholar
• BOTTINO C, FALCO M, PAROLINI S, et al.: NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. " Exp. Med. (2001) 194:235–246.
   Google Scholar
• VITALE M, FALCO M, CASTRICONI R et al.: Identification of NKp80, a novel triggering molecule expressed by human NK cells. Ear. J Immunol. (2001) 31:233–242.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, MUUL LM et al.: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl. J Med. (1985) 313:1485–1492.
   PubMed Web of Science ®Google Scholar
• KIMURA H, YAMAGUCHI Y: A Phase IIIrandomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer (1997) 80:42–49.
   PubMed Web of Science ®Google Scholar
• LAW TM, MOTZER RJ,MAZUMDAR M et al.: Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer (1995) 76:824–832.
   Google Scholar
• CALIGIURI MA, MURRAY C, SOIFFER RJ et al.: Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.j Clin. Omni (1991) 9:2110–2119.
   Google Scholar
• MEROPOL NJ, BARRESI GM, FEHNIGER TA, HITT J, FRANKLIN M, CALIGIURI MA: Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol Immunother: (1998) 46:318–326.
   PubMed Web of Science ®Google Scholar
• •Describes the in vivo effects on NK cell expansion and activation of the low-dose IL-2 with intermediate-dose pulse IL-2 regimen.
   Google Scholar
• FARAG SS, GEORGE SL, LEE EJ et al.: Postremission therapy with low-dose
   Google Scholar
• ••interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin. Cancer Res. (2002) 8:2812–2819.
   PubMed Web of Science ®Google Scholar
• ATKINS MB, LOTZE MT, DUTCHER JP et al.: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.j Clin. Oncol (1999) 17:2105–2116.
   Google Scholar
• •Therapeutic benefit of high-dose IL-2 in metastatic melanoma.
   Google Scholar
• PARKINSON DR, SZNOL M: High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma. Semin. Oncol (1995) 22:61–66.
   PubMed Web of Science ®Google Scholar
• BENYUNES MC, HIGUCHI C, YORK A et al.: Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant. (1995) 16:283–288.
   PubMed Web of Science ®Google Scholar
• BAUER M, REAMAN GH, HANK JA et al.: A Phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer (1995) 75:2959–2965.
   PubMed Web of Science ®Google Scholar
• SHIBAGAKI R, KISHIMOTO S, TAKENAKA H, YASUNO H: Recombinant interleukin 2 monotherapy for classic Kaposi sarcoma. Arch. Dermatol (1998) 134:1193–1196.
   PubMed Web of Science ®Google Scholar
• FISHER RI, ROSENBERG SA, FYFE G:Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancerj Sci. Am. (2000) 6:S55–S57.
   PubMed Web of Science ®Google Scholar
• •Updated results of the beneficial effect of high-dose IL-2 in metastatic renal cell carcinoma.
   Google Scholar
• MELONI G, VIGNETTI M,POGLIANI E et al.: Interleukin-2 therapy in relapsed acute myelogenous leukemia. Cancerj Sci. Am. (1997) 3:S43–S47.
   Google Scholar
• ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ et al.: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 andinterferon alfa-2b. Clin. Oncol (1999) 17:968–975.
   Web of Science ®Google Scholar
• BAXEVANIS CN, DEDOUSSIS GV, PAPADOPOULOS NG et al.: Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor. Cancer (1995) 76:1253–1260.
   PubMed Web of Science ®Google Scholar
• DAVIES FE, RAJE N, HIDESHIMA T et al.: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 98:210–216.
   PubMed Web of Science ®Google Scholar
• GOLAB J, ZAGOZDZON R: Antitumoreffects of interleukin-12 in pre-clinical and early clinical studies (Review). Int. .1 Ma Med. (1999) 3:537–544.
   PubMed Web of Science ®Google Scholar
• •Review of clinical trials of IL-12 in cancer.
   Google Scholar
• LIM SH, NEWLAND AC, KELSEY S et al.: Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia-a Phase II study. Cancer Immunol Immunother. (1992) 34:337–342.
   PubMed Web of Science ®Google Scholar
• CORTES JE, KANTARJIAN HM, O'BRIEN S et al.: A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer (1999) 85:1506–1513.
   Google Scholar
• ITESCU S, ARTRIP JH, KWIATKOWSKI PA et al.: Lysis of pig endothelium by IL-2 activated human natural killer cells is inhibited by swine and human major histocompatibility complex (MHC) class I gene products. Ann. Transplant. (1997) 2:14–20.
   PubMedGoogle Scholar
• WETZLER M, BAER MR, STEWART SJ et al.: HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. Leukemia (2001) 15:128–133.
   PubMed Web of Science ®Google Scholar
• IGARASHI T, SRINIVASAN R, WYNBERG J et al.: Generation of alloreactive NK cells with selective cytotoxicity to melanoma and renal cell carcinoma based on KIR-ligand incompatibility. Blood (2002) 100:73a.
   Web of Science ®Google Scholar
• •An abstract presenting for the first time evidence for the effect of KIR epitope mismatching on alloreactivity of NK cells against solid tumour cells.
   Google Scholar
• FROHN C, HOPPNER M, SCHLENKE P, KIRCHNER H, KORITKE P, LUHM J: Anti-myeloma activity of natural killer lymphocytes. Br. .1 Haematol (2002) 119:660–664.
   Google Scholar
• WEINER M: Monoclonal antibody therapy in cancer. Semin. amyl (1999) 26:43–51.
   Google Scholar
• GOLAY J, ZAFFARONI L, VACCARI T et al.: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody ritwdmab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood (2000) 95:3900–3908.
   PubMed Web of Science ®Google Scholar
• HARJUNPAA A, JUNNIKKALA S, MERI S: Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand. Immunol(2000) 51:634–641.
   PubMed Web of Science ®Google Scholar
• HOFMEISTER JK, COONEY D, COGGESHALL KM: Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells MM. Dis. (2000) 26:133–143.
   PubMed Web of Science ®Google Scholar
• REFF ME, CARNER K, CHAMBERS KS et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood(1994) 83:435–445.
   PubMed Web of Science ®Google Scholar
• CLYNES RA, TOWERS TL, PRESTA LG, RAVETCH JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. (2000) 6:443–446.
   PubMed Web of Science ®Google Scholar
• ••Presents evidence for the importance ofADCC as a mechanism for the in vivo activity of rituximab.
   Google Scholar
• KONO K, TAKAHASHI A, ICHIHARA F, SUGAI H, FUJII H, MATSUMOTO Y: Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res. (2002) 62:5813–5817.
   PubMed Web of Science ®Google Scholar
• MASUCCI G, RAGNHAMMAR P, VVERSALL P, MELLSTEDT H: Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A). Cancer Immunol Immunother:(1990) 31:231–235.
   PubMed Web of Science ®Google Scholar
• CARSON WE, PARIHAR R, LINDEMANN MJ et al: Interleuldn-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur. Immunol (2001) 31:3016–3025.
   PubMed Web of Science ®Google Scholar
• PARIHAR R, DIERKSHEIDE J, HU Y, CARSON WE: IL-12 enhances the natural killer cell cytokine response to Ab-coatedtumor cells. J. Clin. Invest. (2002) 110:983–992.
   PubMed Web of Science ®Google Scholar
• NGUYEN QH, ROBERTS RL, ANK BJ, UN SJ, THOMAS EK, STIEHM ER: Interleukin (IL)-15 enhances antibody-dependent cellular cytotoxicity and natural killer activity in neonatal cells. Cell bninunol. (1998) 185:83–92.
   PubMed Web of Science ®Google Scholar
• DABHOLKAR M, TATAKE R, AMIN K, ADVANI S, GANGAL S: Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission. Oncology (1989) 46:123–127.
   PubMed Web of Science ®Google Scholar
• HANK JA, ROBINSON RR, SURFUS J et al.: Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res. (1990) 50:5234–5239.
   PubMed Web of Science ®Google Scholar
• FRIEDBERG JW, NEUBERG D, GRIBBEN JG et al: Combination immunotherapy with ritwdmab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br. J. Haeinatol (2002) 117:828–834.
   PubMed Web of Science ®Google Scholar
• ANSELL SM, WITZIG TE, KURTIN PJ et al.: Phase I study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood (2002) 99:67–74.
   PubMed Web of Science ®Google Scholar
• WENG W, LEVY R: Ritwdmab-induced antibody-dependent cellular cytotoxicity (ADCC) in follicular non-Hodgkin's lymphoma. Blood (2002) 100:157a.
   Web of Science ®Google Scholar
• KOH CY, BLAZAR BR, GEORGE T et al.: Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood (2001) 97:3132–3137.
   PubMed Web of Science ®Google Scholar
• ••In vivo use of antibody to blockKIR-MHC class I interaction as a means to augment NK cell-mediated killing of neoplastic cells.
   Google Scholar
• VITALE M, BOTTINO C, SIVORI S et al.: NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. Exp. Med. (1998) 187:2065–2072.
   PubMed Web of Science ®Google Scholar
• SANTOURLIDIS S, TROMPETER HI, WEINHOLD S et al.: Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J. bninunol. (2002) 169:4253–4261.
   PubMed Web of Science ®Google Scholar
• GUR H, KRAUTHGAMER R, BERREBI A et al.: Tolerance induction by megadose hematopoeitic progenitor cells: expansion of veto cells by short term culture of purified human CD 34(-i-) cells. Blood (2002) 99:4174–4181.
   PubMed Web of Science ®Google Scholar
• MARTELLI ME AVERSA F, BACHAR-LUSTIG E et al.: Transplants across human leukocyte antigen barriers. Seinin. Heinatol (2002) 39:48–56.
   Google Scholar
• RUGGERI L, CAPANNI M,CASUCCI M et al.: Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood (1999) 94:333–339.
   Google Scholar
• COLONNA M, BORSELLINO G, FALCO M, FERRARA GB, STROMINGER JL: HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc. Natl. Acad. Sci. USA (1993) 90:12000–12004.
   PubMed Web of Science ®Google Scholar
• MANDELBOIM 0, REYBURN HT, VALES-GOMEZ M et al.: Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J. Exp. Med. (1996) 184:913–922.
   Google Scholar
• RUGGERI L, CAPANNI M, URBANI E et al.: Effectiveness of donor natural killer call alloreactivity in mismatched hematopoietic transplants. Science (2002) 295:2097–3100.
   PubMed Web of Science ®Google Scholar
• ••Excellent review by the Perugia group ofthe biology and clinical efficacy of alloreactive NK cells in the setting of haplotype-mismatched stem cell transplants.
   Google Scholar
• DAVIES SM, RUGGERI L, DEFOR T et al.: Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood (2002) 100:3825–3827.
   Google Scholar
• GEIBEL S, LOCATELLI F,MACCARIO R et al: KIR ligand incompatibility is associated with prolonged survival and lower transplant-related mortality in URD-HSCT recipients. Blood (2002) 100:640a.
   PubMed Web of Science ®Google Scholar
• KEEVER CA, SMALL TN, FLOMENBERG N et al.: Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients ofconventional marrow grafts. Blood (1989) 73:1340–1350.
   PubMed Web of Science ®Google Scholar